title: IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial.
abstract: BACKGROUND
  Studies of IV magnesium sulfate as a treatment for acute asthma have had mixed results, with some data suggesting a benefit for acute severe asthma, but not for mild-to-moderate asthma. In a multicenter cohort, this study tests the hypothesis that administration of magnesium sulfate improves pulmonary function in patients with acute severe asthma.
  
  
  METHODS
  Placebo-controlled, double-blind, randomized clinical trial.
  
  
  METHODS
  Emergency departments (EDs) of eight hospitals.
  
  
  METHODS
  Patients aged 18 to 60 years presenting with acute asthma and FEV1 < or = 30% predicted on arrival to the ED.
  
  
  METHODS
  All patients received nebulized albuterol at regular intervals and IV methylprednisolone. Two grams of IV magnesium sulfate or placebo were administered 30 min after ED arrival. The primary efficacy end point was FEV1 at 240 min, and the data analysis was intent to treat.
  
  
  RESULTS
  Two hundred forty-eight patients were included, and the mean FEV1 on ED arrival was 22.9% predicted. At 240 min, patients receiving magnesium had a mean FEV1 of 48.2% predicted, compared to 43.5% predicted in the placebo-treated group (mean difference, 4.7%; 95% confidence interval [CI], 0.29 to 9.3%; p = 0.045). A regression model confirmed the effect of magnesium compared to placebo was greater in patients with a lower initial FEV1 (p < 0.05). If the initial FEV1 was < 25% predicted, the final FEV1 was 45.3% predicted in the magnesium-treated group and 35.6% predicted in the placebo-treated group (mean difference, 9.7%; 95% CI, 4.0 to 15.3%; p = 0.001). If the initial FEV was > or = 25% predicted, magnesium administration was not beneficial; the final FEV1 was 51.1% predicted in the magnesium-treated group and 53.9% predicted in the placebo-treated group (mean difference, - 2.9%, 95% CI, - 9.4 to 3.7; p = not significant). Overall, the use of magnesium sulfate did not improve hospital admission rates.
  
  
  CONCLUSIONS
  Administration of 2 g of IV magnesium sulfate improves pulmonary function when used as an adjunct to standard therapy in patients with very severe, acute asthma.
authors.affiliation: Department of Emergency Medicine, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA. aresilv@aol.com
authors.forename: Robert A
authors.initials: RA
authors.lastname: Silverman
authors.forename: Harold
authors.initials: H
authors.lastname: Osborn
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Runge
authors.forename: E John
authors.initials: EJ
authors.lastname: Gallagher
authors.forename: William
authors.initials: W
authors.lastname: Chiang
authors.forename: James
authors.initials: J
authors.lastname: Feldman
authors.forename: Theodore
authors.initials: T
authors.lastname: Gaeta
authors.forename: Katherine
authors.initials: K
authors.lastname: Freeman
authors.forename: Bruce
authors.initials: B
authors.lastname: Levin
authors.forename: Noel
authors.initials: N
authors.lastname: Mancherje
authors.forename: Steven
authors.initials: S
authors.lastname: Scharf
mesh_terms: D000208:Acute Disease; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007275:Injections, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D013997:Time Factors
chemical_list: D018927:Anti-Asthmatic Agents; D008278:Magnesium Sulfate